Gene array analysis comparison between rat collagen-induced arthritis and human rheumatoid arthritis

被引:20
作者
Soto, H. [1 ]
Hevezi, P. [1 ]
Roth, R. B. [1 ]
Pahuja, A. [1 ]
Alleva, D. [1 ]
Acosta, H. M. [2 ]
Martinez, C. [2 ]
Ortega, A. [2 ]
Lopez, A. [2 ]
Araiza-Casillas, R. [2 ,3 ]
Zlotnik, A. [1 ]
机构
[1] Neurocrine Biosci, San Diego, CA USA
[2] Univ Autonoma Baja California, Sch Med, Mexicali 21100, Baja California, Mexico
[3] Hosp Especialidades IMSS, Dept Internal Med Rheumatol, Mexicali, Baja California, Mexico
关键词
D O I
10.1111/j.1365-3083.2008.02117.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Collagen-induced arthritis (CIA) is an experimental arthritis model used to study the inflammatory processes in this disease and test potential therapeutics. In order to better characterize this model, we conducted the first comprehensive gene expression analysis of rat CIA. To evaluate how closely the rat model reflects human rheumatoid arthritis (RA), we also analysed gene expression in human RA, using genome-wide Affymetrix genearrays. By applying multiple strategies, including comparison of the highest induced genes, expression of immunological-associated genes as well as Ingenuity Pathway Analysis (IPA), we were able to compare the two expression profiles. Among the highest induced genes in RA were several B-cell-associated genes, including immunoglobulins, B-cell markers such as CD20, and cytokines and chemokines that act on B cells such as TNFSF13b/BLyS and CXCL13, none of which was upregulated in CIA. The latter was instead characterized by the upregulation of genes expressed primarily in macrophages and dendritic cells. Of the 22 pathways identified as significant in both diseases by IPA, only three (IL6, chemokine signalling and antigen presentation) were present in both settings. We conclude that there are significant differences in the inflammatory mechanisms between human RA and rat CIA, and that genome-wide comparative gene expression analyses are useful tools to evaluate the relevance of animal models to human disease.
引用
收藏
页码:43 / 57
页数:15
相关论文
共 45 条
  • [1] Gene expression profiling in murine autoimmune arthritis during the initiation and progression of joint inflammation
    Adarichev, VA
    Vermes, C
    Hanyecz, A
    Mikecz, K
    Bremer, EG
    Glant, TT
    [J]. ARTHRITIS RESEARCH & THERAPY, 2005, 7 (02) : R196 - R207
  • [2] ARNETT FC, 1989, B RHEUM DIS, V38, P1
  • [3] Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation
    Baramova, EN
    Bajou, K
    Remacle, A
    LHoir, C
    Krell, HW
    Weidle, UH
    Noel, A
    Foidart, JM
    [J]. FEBS LETTERS, 1997, 405 (02) : 157 - 162
  • [4] Proteolytic activation of alternative CCR1 ligands in inflammation
    Berahovich, RD
    Miao, ZH
    Wang, Y
    Premack, B
    Howard, MC
    Schall, TJ
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (11) : 7341 - 7351
  • [5] Strategies using functional genomics in rheumatic diseases
    Burmester, GR
    Häupl, T
    [J]. AUTOIMMUNITY REVIEWS, 2004, 3 (7-8) : 541 - 549
  • [6] Matrix metalloproteinases: Role in arthritis
    Burrage, PS
    Mix, KS
    Brinckerhoff, CE
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 : 529 - 543
  • [7] A network-based analysis of systemic inflammation in humans
    Calvano, SE
    Xiao, WZ
    Richards, DR
    Felciano, RM
    Baker, HV
    Cho, RJ
    Chen, RO
    Brownstein, BH
    Cobb, JP
    Tschoeke, SK
    Miller-Graziano, C
    Moldawer, LL
    Mindrinos, MN
    Davis, RW
    Tompkins, RG
    Lowry, SF
    [J]. NATURE, 2005, 437 (7061) : 1032 - 1037
  • [8] DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets
    Devauchelle, V
    Marion, S
    Cagnard, N
    Mistou, S
    Falgarone, G
    Breban, M
    Letourneur, F
    Pitaval, A
    Alibert, O
    Lucchesi, C
    Anract, P
    Hamadouche, M
    Ayral, X
    Dougados, M
    Gidrol, X
    Fournier, C
    Chiocchia, G
    [J]. GENES AND IMMUNITY, 2004, 5 (08) : 597 - 608
  • [9] Anti-TNF therapy: Where have we got to in 2005?
    Feldmann, M
    Brennan, FM
    Foxwell, BMJ
    Taylor, PC
    Williams, RO
    Maini, RN
    [J]. JOURNAL OF AUTOIMMUNITY, 2005, 25 : 26 - 28
  • [10] Feldmann Marc, 2004, Novartis Found Symp, V256, P53